/
Login
Analysis Scores
Lothien Robustness Score?
85/100
Very Strong
The factor score and time-horizon weights were measured only on the past data of companies that trade today; companies that left the exchange in the past are not part of this measurement.
Neden bu skor?
Damodaran ?
65/100
Dalio Risk ?
99/100
Piotroski ?
0/9
Weak
Previous period ROA data missing (C1 delta-ROA); Total assets data missing → ROA cannot be calculated (C2); Operating cash flow data missing (C3, C4); Önceki yıl borç/varlık verisi yok → kaldıraç azalması kontrol edilemedi (C5); Current ratio data missing (C6); Previous year data missing → margin comparison unavailable (C8); current assets data missing → turnover calculation unavailable (C9)
Graham ?
Veri Yetersiz
Özkaynaklar negatif veya sıfır — Graham formülü pozitif defter değeri gerektirir
Active Metric?
4/4
Confidence?
75%
Lothien Robustness Summary
100/100
Lothien Sağlamlık: Çok Güçlü (100/100)
Temel göstergelerin büyük çoğunluğu pozitif. Kârlılık, büyüme ve değerleme açısından güçlü görünüm. | Kısa Vade: Olumlu | Uzun Vade: Olumlu | Pozitif: 12 | Negatif: 0 | Nötr: 0
Net Kâr Pozitif
Son çeyrekte ₹13.1B net kâr açıklandı. Şirket kârlı.
Çeyreklik Kâr Artışı
Net kâr bir önceki çeyreğe göre %+25.4 arttı (₹10.4B → ₹13.1B). Kısa vadede olumlu momentum.
Yıllık Kâr Büyümesi Güçlü
Geçen yılın aynı dönemine göre net kâr %+159.4 arttı. Büyüme trendi sağlıklı.
4 Çeyrek Üst Üste Artış
Son 4 çeyrek üst üste kâr artıyor. Güçlü yukarı trend devam ediyor.
Hasılat Büyümesi Güçlü
Satış gelirleri çeyreklik %+32.7 arttı (₹15.1B → ₹20.1B). Talep güçlü.
Yıllık Hasılat Büyümesi Güçlü
Yıllık hasılat %+66.9 arttı. Şirket büyüyor.
Brüt Marj Genişliyor
Brüt kâr marjı %52.8 → %64.3 (+11.5 puan). Fiyatlama gücü artıyor veya maliyetler düşüyor.
Yüksek Net Kâr Marjı
Net kâr marjı %65.3. Her 100₹ satıştan 65₹ kâr kalıyor.
FAVÖK Büyümesi
FAVÖK çeyreklik %+30.0 arttı (₹10.7B → ₹13.8B). Operasyonel verimlilik artıyor.
Çok Düşük F/K
Trailing F/K: 5.7. Piyasa şirketi kârına göre düşük fiyatlıyor. Ucuz görünüyor ama sebebi araştırılmalı.
Düşük EV/EBITDA
EV/EBITDA: 4.6. Operasyonel kârlılığa göre ucuz değerleme.
Lothien Sağlamlık Skoru: 85/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı güçlü görünüyor.
Data date 2026-10-23 Not investment advice; the figures are rule-based model output. How the scores are computed
Score record
Method
How the scores are computed
· Scorecard
Data date
2026-10-23
Update frequency
Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run
Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.
AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.
Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.
WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.
Model output; not investment advice; different models can disagree. Report an error
Risk Analysis (VaR)
Orta
252 days
Annual Volatility ?
%34.6
VaR 95% ?
%3.42
daily max loss
VaR 99% ?
%4.90
daily max loss
CVaR 95% ?
%4.70
expected loss (tail)
Max Drawdown ?
%25.7
21.05.2026 → 17.08.2026
Skewness ?
-0.01
Parametrik%3.42
Historik%2.91
Cornish-Fisher%3.31
Return Distribution
Valuation
Potential?
+123.1%
ROIC ?
18.5%
DCF Value ?
2,701.34
Debt Cycle?
Early Expansion
Balance Sheet Analysis?
Q2026/6
Net kâr çeyreklik %+25.4 artarak 13.1B INR oldu
Yıllık net kâr büyümesi %+159.4
Hasılat çeyreklik %+32.7 büyüdü (20.1B INR)
Yıllık hasılat büyümesi güçlü (%+66.9)
Brüt kâr marjı güçlü: %64.3
Brüt marj değişimi: %+11.5 puan
Net kâr marjı yüksek: %65.3
FAVÖK çeyreklik %+30.0 büyüdü (13.8B INR)
FAVÖK marjı güçlü: %69.1
İşletme kârı pozitif: 10.9B INR
İşletme kârı büyüme: %+94.6
Faiz karşılama oranı güçlü: 69.4x (Faiz: 199.4M INR)
Ödenmiş sermaye: 142.8M INR
Son 5 çeyrek ardışık kâr
Fiyat TRAMA-99 hafif üzerinde: %+4.8
Destek seviyesi: TRAMA-99 = 1427.94 INR
Fundamental & Technical Analysis
Profitability
Net Profit Margin
%65.3
Net profit margin %65.3 — very strong. Compared to previous quarter -3.8 point decrease.
ROE - Return on Equity (TTM)
%23.3
ROE %23.3 — high return on equity.
EBITDA Margin
%69.1
EBITDA margin %69.1 — operationally very efficient.
Gross Profit Margin
%64.3
Gross profit per revenue %64.3. Strong pricing power.
Valuation
P/E Ratio
5.7x
Sector: 59.8x
F/K 5.7x — sector median's (59.8x) %90 below. Attractive for value investing.
P/B Ratio
1.26x
Sector: 3.92x
PD/DD 1.26x — sector median's (3.92x) well below. Cheap relative to book value.
EV/EBITDA
4.6x
Sector: 26.6x
EV/EBITDA 4.6x — sector median's (26.6x) %83 below. Cheap relative to EBITDA.
Indebtedness
Current Ratio
7.13x
Current ratio 7.13x — current assets are 2x short-term liabilities. Very healthy liquidity.
Net Debt / EBITDA
0.3x
Net Debt/EBITDA 0.3x — very low debt burden. Company can repay debt quickly.
Debt / Equity
0.06x
Low leverage — majority of assets financed by equity.
Interest Coverage
35.6x
Interest coverage 35.6x — very wide margin for paying interest expenses.
Growth
Revenue Growth (YoY)
%+66.9
Revenue YoY %66.9 grew (2026/6) — strong growth. Sector expansion and/or market share increase.
Net Profit Growth (YoY)
%+159.4
Net profit YoY %159.4 increased (2026/6) — extraordinary profit growth.
Score Explanations
Lothien Robustness
85/100
Very strong robustness score (85/100). Damodaran valuation, Dalio risk analysis and balance sheet quality criteria are largely met.
Very Strong
Potential
+123.1%
Plus %123.1 expected value (3339.10) vs current price comparison. 4/4 valuation models could be calculated. Model confidence %75.
Components: PE target: 4489.80 | P/B target: 4489.80 | EV/EBITDA target: 4489.80 | DCF target: 2701.34
Damodaran Valuation
65/100
Moderate Damodaran score (65/100). ROIC (%18.5) – WACC (%16.2) difference +2.3 bps. Value creation capacity limited.
Moderate
Dalio Risk Analysis
99/100
Low debt risk (99/100). Interest coverage ratio 35.6x — strong. Debt/EBITDA 0.3x — in healthy range.
Leverage: 98/100 | Debt Service: 100/100 | Quality: 99/100
ROIC - Return on Capital
%18.5
ROIC (%18.5) slightly exceeds cost of capital (2.3 points).
WACC: %16.2
DCF Discounted Cash Flow
2,701.34
DCF modeli 2701.34 target value produced — compared to current price %80.5 undervalued.
Current price: 1496.60
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
0/9
Weak Piotroski (0/9). Many balance sheet quality criteria not met. Note: Previous period ROA data missing (C1 delta-ROA); Total assets data missing → ROA cannot be calculated (C2)
Weak
Graham Intrinsic Value
—
⚖️ Sector Comparison
P/E Ratio
5.7x
vs 59.8x
Sector median's %90 below — cheap
P/B Ratio
1.26x
vs 3.92x
Compared to sector %68 cheaper (by book value)
EV/EBITDA
4.6x
vs 26.6x
Compared to sector %83 lower EV/EBITDA
ROIC vs WACC
%18.5
vs %16.2 WACC
ROIC 2.3 bps above cost of capital
Net Profit Margin (TTM)
%60.3
vs %63.8 EBITDA margin
TTM net profit margin %60.3
TRAMA-99 Trend — Near TRAMA
Price (1496.60), TRAMA-99 line (1427.94) at close levels (%+4.8). Important decision zone — breakout direction will determine the trend.
Price:: 1496.60
TRAMA: 1427.94
Difference: %+4.8
Charts
Indicators
BB deviation
?
RSI thresholds
?
GESHIP — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.